JO3261B1 - مشتق بيريدين أحادي الحلقة - Google Patents

مشتق بيريدين أحادي الحلقة

Info

Publication number
JO3261B1
JO3261B1 JOP/2014/0039A JOP20140039A JO3261B1 JO 3261 B1 JO3261 B1 JO 3261B1 JO P20140039 A JOP20140039 A JO P20140039A JO 3261 B1 JO3261 B1 JO 3261B1
Authority
JO
Jordan
Prior art keywords
group
hydrogen atom
present
alkoxy
pharmaceutically acceptable
Prior art date
Application number
JOP/2014/0039A
Other languages
English (en)
Inventor
Ohashi Isao
Okada Toshimi
Nagao Satoshi
Funasaka Setsuo
Tanaka Keigo
Nakatani Yusuke
Yamane Yoshinobu
Karoji Yuki
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of JO3261B1 publication Critical patent/JO3261B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتقديم مركب جديد له نشاط مثبط لـ FGFR أو ملح مقبول صيدلانيا منه، وتركيبة صيدلانية تتضمنه. بصفة خاصة، يقدم الاختراع الحالي مركب ممثل بالصيغة التالية (I) أو ملح مقبول صيدلانيا منه: حيث n تمثل 0 الى 2؛ A تمثل مجموعة أريلين أو مجموعة أريلين غير متجانسة؛ G تمثل رابطة فردية، ذرة أكسجين أو -CH 2 - ؛ E تمثل سيكل غير متجانسة غير عطرية تتضمن نيتروجين؛ R1 تمثل مجموعة ألكوكسي، مجموعة ألكوكسي ألكوكسي أو ما شابه ذلك؛ R2 تمثل ذرة هيدروجين، ذرة هالوجين، مجموعة هيدروكسيل، مجموعة ألكيل، مجموعة هيدروكسي ألكيل، مجموعة سيكليك غير متجانسة غير عطرية تتضمن نيتروجين أو ما شابه ذلك؛ و R3 تمثل ذرة هيدروجين، مجموعة ألكيل، مجموعة ألكوكسي أو ما شابه ذلك، بشرط أنه عندما تكون E تمثل حلقة أزيتيدين و R2 أو تكون R3 موجودة على ذرة نيتروجين على حلقة الأزيتيدين، R2 أو R3 لا تمثل ذرة هيدروجين.
JOP/2014/0039A 2013-02-20 2014-02-18 مشتق بيريدين أحادي الحلقة JO3261B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361766922P 2013-02-20 2013-02-20

Publications (1)

Publication Number Publication Date
JO3261B1 true JO3261B1 (ar) 2018-09-16

Family

ID=51351646

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0039A JO3261B1 (ar) 2013-02-20 2014-02-18 مشتق بيريدين أحادي الحلقة

Country Status (35)

Country Link
US (1) US8933099B2 (ar)
EP (1) EP2960238B1 (ar)
JP (2) JP5600229B1 (ar)
KR (1) KR102050128B1 (ar)
CN (1) CN105073730B (ar)
AR (1) AR094812A1 (ar)
AU (1) AU2014219811B2 (ar)
BR (1) BR112015019790B1 (ar)
CA (1) CA2901585C (ar)
CL (1) CL2015002311A1 (ar)
CY (1) CY1119220T1 (ar)
DK (1) DK2960238T3 (ar)
ES (1) ES2628495T3 (ar)
HR (1) HRP20170873T1 (ar)
HU (1) HUE032931T2 (ar)
IL (1) IL240623B (ar)
JO (1) JO3261B1 (ar)
LT (1) LT2960238T (ar)
ME (1) ME02755B (ar)
MX (1) MX361870B (ar)
MY (1) MY178760A (ar)
NZ (1) NZ711101A (ar)
PE (1) PE20151509A1 (ar)
PH (1) PH12015501813A1 (ar)
PL (1) PL2960238T3 (ar)
PT (1) PT2960238T (ar)
RS (1) RS56064B1 (ar)
RU (1) RU2645352C2 (ar)
SG (1) SG11201506488WA (ar)
SI (1) SI2960238T1 (ar)
SM (1) SMT201700288T1 (ar)
TW (4) TWI672140B (ar)
UA (1) UA116794C2 (ar)
WO (1) WO2014129477A1 (ar)
ZA (1) ZA201505941B (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017002268B1 (pt) * 2014-08-18 2022-11-08 Eisai R&D Management Co., Ltd Sal de derivado de piridina monocíclica e cristal do mesmo
RU2712222C2 (ru) * 2015-03-25 2020-01-27 Нэшнл Кэнсер Сентер Терапевтическое средство против рака желчных протоков
WO2017104739A1 (ja) 2015-12-17 2017-06-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤
CN107098884A (zh) * 2016-02-19 2017-08-29 中国科学院上海药物研究所 一类取代的氨基吡啶类化合物及其制备和用途
JP2020536846A (ja) * 2017-10-12 2020-12-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｆｇｆｒ選択的チロシンキナーゼ阻害剤を含む医薬組成物
BR112020017922A2 (pt) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. Agente terapêutico para carcinoma hepatocelular
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021255084A1 (en) * 2020-04-17 2022-12-08 Eisai R&D Management Co., Ltd. Breast cancer therapeutic agent
KR20230047056A (ko) 2020-07-31 2023-04-06 에자이 알앤드디 매니지먼트 가부시키가이샤 유방암 치료제
TW202233185A (zh) 2020-10-28 2022-09-01 日商衛材R&D企管股份有限公司 腫瘤治療用醫藥組合物
JP2023099776A (ja) * 2021-08-31 2023-07-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の合成中間体の製造方法
JP2023099778A (ja) * 2021-08-31 2023-07-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の製造方法
EP4361143A4 (en) * 2021-08-31 2025-05-28 Eisai R&D Management Co., Ltd. Process for the preparation of a monocyclic pyridine derivative
TW202328098A (zh) 2021-08-31 2023-07-16 日商衛材R&D企管股份有限公司 單環吡啶衍生物的合成中間體之製造方法
CA3244743A1 (en) * 2022-03-18 2025-06-13 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences SALT OF A SIX-LINK AMINO-SUBSTITUTE NITRIC HETEROCYCLIC COMPOUND, CRYSTALLINE FORM THEREIN, CORRESPONDING PREPARATION PROCESS AND ASSOCIATED USE
CN120021412A (zh) * 2023-09-18 2025-05-20 上海润石医药科技有限公司 包含杂芳基氧基萘类化合物的药物组合物及其制备方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
US6949585B2 (en) 2001-04-03 2005-09-27 Eisai Co., Ltd. Cyclooctanone derivatives and cyclodecanone derivative, and use thereof
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2004020434A1 (ja) * 2002-08-30 2004-03-11 Eisai Co., Ltd. 含窒素芳香環誘導体
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CN100497339C (zh) 2003-04-10 2009-06-10 霍夫曼-拉罗奇有限公司 嘧啶并化合物
US20050256154A1 (en) 2004-05-04 2005-11-17 Kin-Chun Luk 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
NZ563692A (en) * 2005-05-23 2011-04-29 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
MEP3808A (xx) 2005-12-21 2010-02-10 Novartis Ag Derivati pirimidinil aril uree kao fgf inhibitori
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1891955A1 (en) 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
MX2009006704A (es) 2006-12-22 2009-06-30 Astex Therapeutics Ltd Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MX2009006706A (es) 2006-12-22 2009-07-02 Astex Therapeutics Ltd Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
WO2009001070A1 (en) 2007-06-25 2008-12-31 Qinetiq Limited Heater suitable for use in a preconcentrator device
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
WO2009076660A2 (en) * 2007-12-13 2009-06-18 Tyratech, Inc. Organic absorbent material and uses thereof
CL2008003675A1 (es) * 2007-12-13 2009-03-20 Wyeth Corp Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparacion, composicion farmaceutica, util para reducir la actividad incrementada de una enzima en un mamifero, en donde dicha enzima es una proteina quinasa, destinado al tratamiento de la inflamacion, asma, colitis, esclerosis multiple, soriasis, artritis reumatoide.
MY155535A (en) 2008-05-23 2015-10-30 Novartis Ag Derivatives of quinolines and quinoxalines as protien tyrosine kinase inhibitors
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2009153592A1 (en) 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
CA2748491C (en) 2008-12-30 2019-08-06 Arqule, Inc. Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
CA2748276A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
EP2379556A1 (en) 2008-12-30 2011-10-26 ArQule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
US9002427B2 (en) 2009-03-30 2015-04-07 Lifewave Biomedical, Inc. Apparatus and method for continuous noninvasive measurement of respiratory function and events
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
FR2947546B1 (fr) 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
EP2270043A1 (en) 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
PT2471786E (pt) 2009-08-07 2016-03-04 Hoffmann La Roche Derivado de aminopirazol
IN2012DN03180A (ar) 2009-10-30 2015-09-25 Novartis Ag
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
WO2013108809A1 (ja) 2012-01-19 2013-07-25 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物及びその塩
EP2821402B1 (en) 2012-02-28 2019-08-21 Astellas Pharma Inc. Nitrogen-containing aromatic heterocyclic compound
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
DK2872491T3 (da) 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitorer af fibroblastvækstfaktorreceptoren
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
SG11201502455TA (en) 2012-09-27 2015-05-28 Chugai Pharmaceutical Co Ltd Fgfr3 fusion gene and pharmaceutical drug targeting same
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑

Also Published As

Publication number Publication date
CN105073730A (zh) 2015-11-18
JPWO2014129477A1 (ja) 2017-02-02
EP2960238A4 (en) 2016-08-17
TWI672139B (zh) 2019-09-21
UA116794C2 (uk) 2018-05-10
ZA201505941B (en) 2016-07-27
BR112015019790B1 (pt) 2020-12-01
CL2015002311A1 (es) 2016-02-05
MX361870B (es) 2018-12-18
TW201900169A (zh) 2019-01-01
DK2960238T3 (en) 2017-06-26
KR20150118151A (ko) 2015-10-21
CN105073730B (zh) 2017-10-13
AR094812A1 (es) 2015-08-26
TW201900168A (zh) 2019-01-01
EP2960238A1 (en) 2015-12-30
HUE032931T2 (en) 2017-11-28
NZ711101A (en) 2018-08-31
TWI672296B (zh) 2019-09-21
RU2015134558A (ru) 2017-03-24
LT2960238T (lt) 2017-07-10
MY178760A (en) 2020-10-20
PH12015501813A1 (en) 2015-12-07
PL2960238T3 (pl) 2017-09-29
MX2015010698A (es) 2016-04-11
BR112015019790A2 (pt) 2017-07-18
TWI641602B (zh) 2018-11-21
US8933099B2 (en) 2015-01-13
PT2960238T (pt) 2017-06-05
HRP20170873T1 (hr) 2017-09-08
TW201439085A (zh) 2014-10-16
WO2014129477A1 (ja) 2014-08-28
IL240623B (en) 2019-03-31
SG11201506488WA (en) 2015-09-29
SI2960238T1 (sl) 2017-07-31
JP5600229B1 (ja) 2014-10-01
PE20151509A1 (es) 2015-10-18
IL240623A0 (en) 2015-10-29
ME02755B (me) 2018-01-20
CA2901585C (en) 2019-09-24
CA2901585A1 (en) 2014-08-28
KR102050128B1 (ko) 2019-11-28
TWI672140B (zh) 2019-09-21
US20140235614A1 (en) 2014-08-21
ES2628495T3 (es) 2017-08-03
AU2014219811B2 (en) 2017-09-28
JP2014237707A (ja) 2014-12-18
EP2960238B1 (en) 2017-04-05
RS56064B1 (sr) 2017-10-31
TW201902889A (zh) 2019-01-16
CY1119220T1 (el) 2018-02-14
RU2645352C2 (ru) 2018-02-21
AU2014219811A1 (en) 2015-09-03
SMT201700288T1 (it) 2017-07-18
HK1215949A1 (en) 2016-09-30

Similar Documents

Publication Publication Date Title
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
UA118259C2 (uk) Гетероциклічні аміди як інгібітори кінази
MX2017010735A (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
EA201690127A1 (ru) Состав на основе ингибиторов syk
NZ710052A (en) Novel pyrazol derivatives
MX2017005158A (es) Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk).
IN2014DN07283A (ar)
PH12018501181A1 (en) Phenyl derivatives as cannabinoid receptor 2 agonists
MX368178B (es) Compuestos de ácido dimetilbenzoico.
MX2015017156A (es) Inhibidores de bace.
PH12020500292A1 (en) Pyridine compound substituted with azole
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
PH12018502012B1 (en) Griseofulvin compound
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
PH12016500152A1 (en) Novel triazine derivative
MD20150103A2 (ro) Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
EP3769757A3 (en) Imaging histone deacetylases with a radiotracer using positron emission tomography
MX2015007309A (es) Derivado de hidantoina.
BR112015023280A2 (pt) derivados de dihidroquinolin-2-ona para utilização como inibidores da aldosterona sintase
PH12016501645A1 (en) Aminopyrazolone derivative